Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial

Fig. 2

Median change from baseline in IgG (a), anti-Smith (b), and anti-cardiolipin IgM (c). A Data were assessed for significance in all patients. B Data were assessed for significance in patients with anti-Smith ≥30 IU/mL. C Data were assessed for significance in patients with anti-cardiolipin IgM>12 MPL at baseline. *p ≤ 0.05, **p ≤ 0.01 for BARI vs. PBO. BARI, baricitinib; Ig, immunoglobulin; PBO, placebo; MPL, IgM phospholipid units

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us